MEMBRANE-ACTIVE AGENTS

TSG is developing drug candidates that attack the lipid envelope target, demonstrating potent antiviral results against diverse classes of viruses and unprecedented potential for treatment of mosquito-borne viral infections.

Modeled after viral-encoded amino acid sequences that confer membrane curvature-sensing properties, our drug candidate demonstrates especially potent activity against viruses between 10-250 nanometers in diameter while leaving much larger human cells unharmed.

The result is a therapeutically safe peptide molecule that effectively destroys a wide variety of enveloped viruses before they enter the cell, providing both therapeutic and preventative applications against a diverse spectrum of harmful virus species.

In addition, because it is a short amphipathic peptide, it is well suited to conventional chemical mass production, enabling rapid scale-up in times of urgent need and allowing for crucial preparation against future bioterror threats.

Potent and Selective Antiviral Activity


In advanced in vivo mouse model studies involving Dengue and Zika viral infections, late-stage therapeutic treatment with TSG’s drug candidate eliminated >99% of viral particles and enabled survival against lethal infections, safely and with no side effects. Additional studies demonstrated that our drug candidate has high selectivity for these viral particles over healthy human cells (up to 1000-fold and beyond), resulting in an excellent therapeutic index. Furthermore, independent tests conducted at the US Army Medical Research Institute of Infectious Diseases, the US National Institutes of Health, WHO Collaborating Centre for Research on Rabies Pathogenesis and Prevention and UK National Infection Service provide strong, research-backed evidence that TSG’s drug candidate works against a wide range of Mosquito-Borne Virus Infections (MBVIs) including Zika, Dengue, Yellow Fever, Japanese Encephalitis, and Chikungunya, as well as retroviruses (HIV), hepaciviruses (Hepatitis C), bunyaviruses (Rift Valley Fever) and mononegaviruses (Rabies, Ebola, Marburg).